AIM: To evaluate the clinical effects of argon laser photocoagulation combined with intravitreous injection of Lucentis on ischemic central retinal vein occlusion(CRVO)associated with macular edema and neovascular retina.

METHODS: This retrospective study analyzed therapeutic effects of argon laser photocoagulation combined with intravitreous injection of Lucentis performed on 24 patients(24 eyes)with CRVO between January in 2012 and May in 2013. Observation was made in terms of clinical data including patients' best-corrected visual acuity, intraocular pressure, optical coherence tomography and fluoresce infundus angiography before treatment and 1wk, 1, 3, 6mo after treatment. Comparative analysis was made regarding the manifestations by fundus fluorescein angiography(FFA)and the changes of central macular retinal thickness central macular retinal thickness(CMT)by optical coherence tomography(OCT)before treatment and 1, 3, 6mo after treatment.

RESULTS: Followed for more than 6mo, 20 patients'(83%)best-corrected visual acuity were improved inordinately; 17 patients'(71%)macular edema was obviously alleviated or disappeared; 4 patients, visual acuities weren't improved. Iris neovascularization gradually disappeared after 1mo treatment and secondary neovascular glaucoma didn't occur in one patient.

CONCLUSION: Argon laser photocoagulation combined with intravitreous injection of Lucentis is an effective method to treat ischemic central retinal vein occlusion. It can improve visual acuity, promote the absorption of retinal hemorrhage, effusion and macular edema, reduce neovascularizations caused by CRVO and obviously prevent the occurrence of secondary neovascular glaucoma.